Back to search

Article

Dapagliflozin Ameliorates Myocardial Ischemia/Reperfusion Injury by Modulating EGFR Signaling and Targeting NCOA4-mediated Ferritinophagy

2024-10-17

Abstract excerpt

<title>Abstract</title> <p>SGLT2 inhibitor dapagliflozin (Dapa) has gained increasing attention in the treatment of myocardial ischemia-reperfusion injury (IRI). However, the mechanism of action of the cardiovascular benefits of Dapa is unclear. The present study aimed to investigate the effects of Dapa on myocardial IRI and the underlying molecular mechanisms. The effects of Dapa on myocardial IRI were investiga...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
28b5417b-b7e4-5377-ab80-a3378a5561ee
DOI
10.21203/rs.3.rs-5172738/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Dapagliflozin Ameliorates Myocardial Ischemia/Reperfusion Injury by Modulating EGFR Signaling and Targeting NCOA4-mediated FerritinophagyDOI 10.21203/rs.3.rs-5172738/v1
Select a neighboring publication to make it the new centre.